Clinical Trials Directory

Trials / Recruiting

RecruitingNCT00390104

Molecular Analysis of Patients With Neuromuscular Disease

Molecular Analysis of Nucleic Acids Derived From Patients With Neuromuscular Disease and Their Family Members

Status
Recruiting
Phase
Study type
Observational
Enrollment
1,000 (estimated)
Sponsor
Boston Children's Hospital · Academic / Other
Sex
All
Age
1 Week – 100 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to identify new genes responsible for neuromuscular disorders and study muscle tissue of patient with known neuromuscular disease, as well as their family members. We are interested in recruiting many types of neuromuscular disease including; Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and limb-girdle muscle dystrophy (LGMD). There are still many patients diagnosed with muscular dystrophy with no causative gene implicated in their disease. Using molecular genetics to unravel basis of these neuromuscular disorders will lead to more accurate diagnosis/prognosis of these disorders which will lead to potential therapies.

Detailed description

We are looking to discover new disease genes responsible for the neuromuscular diseases found in our participants and their families. Our research lab has a long history of identifying novel genes responsible for various forms of neuromuscular disease including; DMD gene, the sarcoglycans, obscurin, and filamin. Each discovery has resulted in advances in our ability to develop diagnostic tests which benefit patients and their families by providing accurate diagnosis, presymptomatic and/or prenatal testing. Genotype-phenotype correlation studies have increased our understanding of the natural history of these rare disorders benefiting patients through better prognostic determinations by clinicians. Biochemical and pathological analysis of muscle biopsy samples in patients with known and unknown types of neuromuscular disease has led to new insights into disease pathophysiology, which we hope will aid in finding new treatments.

Conditions

Timeline

Start date
2002-01-01
Primary completion
2026-12-31
Completion
2027-12-31
First posted
2006-10-19
Last updated
2023-04-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00390104. Inclusion in this directory is not an endorsement.